Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Treatment adherence

    Maintain Oral Adherence With ONS Guidelines™
    Research

    Maintain Oral Adherence With ONS Guidelines™

    With so many of today’s cancer treatments administered orally, ensuring that patients adhere to their regimen as prescribed is essential to optimal outcomes. According to the World Health Organization, medication adherence is the single most important modifiable factor that affects treatment outcomes.

    June 14, 2022
    APRN Roles Evolve to Address Cancer Screening, Treatment Adherence, and Public Health
    Advanced Practice Nursing (APRN)

    APRN Roles Evolve to Address Cancer Screening, Treatment Adherence, and Public Health

    Responses to pandemic-related screening and treatment delays have created new opportunities for oncology advanced practice RNs (APRNs), too. In both their institutions and communities, APRNs are guiding patients and providers to reverse the increases in late cancer diagnoses, morbidity, and mortality—ultimately improving outcomes.

    April 14, 2022
    The Case of the GVHD Double-Take
    Treatment side effects

    The Case of the GVHD Double-Take

    Jeff is a 60-year-old patient with myeloproliferative disease. After his care team secured a 9/10 match, he received an allogeneic hematopoietic stem cell transplantation with a conditioning regimen of fludarabine and melphalan. Neutrophil engraftment occurred at day 20, and he was discharged to home shortly after engraftment. One month later, he presented to the clinic with abdominal pain and a new diffuse erythematous rash, which his care team initially treated with corticosteroids. However, his abdominal pain persisted, and Jeff was admitted to the hospital a few days later for further workup for suspected acute graft-versus-host disease (GVHD). A computed tomography scan of his abdomen demonstrated worsening enterocolitis because of Yersinia enterocolitica. What would you do?

    August 24, 2021
    Oncology Drug Reference Sheet: Tepotinib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tepotinib

    Tepotinib (Tepmetko®) was granted accelerated approval in February 2021 for mesenchymalepithelial transition (MET)-altered metastatic non-small cell lung cancer (NSCLC) based on overall response rate and duration. The drug is still under long-term evaluation and healthcare providers should report all serious adverse events that may be associated to FDA’s MedWatch Reporting System.

    June 22, 2021
    Oncology Drug Reference Sheet: Trilaciclib
    Clinical practice

    Oncology Drug Reference Sheet: Trilaciclib

    On February 12, 2021, the U.S. Food and Drug Administration approved trilaciclib (CoselaTM), a parenteral inhibitor of cyclin-dependent kinase, to prevent myelosuppression when administered prior to chemotherapy administration. The approval is currently limited to the use of trilaciclib before treatment with platinum- and etoposide-containing regimens and topotecan-containing regimens for treatment of extensive-stage small cell lung cancer.

    May 25, 2021
    Even Short Treatment Delays Affect Cancer Outcomes
    Research

    Even Short Treatment Delays Affect Cancer Outcomes

    Delaying initiation of cancer treatment by just four weeks is associated with increased mortality rates for patients with seven types of cancers, regardless of treatment type, researchers reported in BMJ.

    February 03, 2021
    ONS Bridge

    Nurses Improve the Care Experience for Bone Marrow Transplant Recipients

    Patients who receive bone marrow transplantations require vigilance for complications such as graft versus host disease, opportunistic infections, and febrile neutropenia. During a presentation for the inaugural ONS Bridge™ virtual conference, Barbara E. Wenger, DNP, APRN, AOCNS®, CRNI, of UCHealth Metro, and Stephanie Armstrong, DNP, AGNP, NP-C, of Froedtert Hospital Clinical Cancer Center, described interventions to improve care quality in the BMT population.

    September 10, 2020
    San Antonio Breast Cancer Symposium

    Social Support May Play a Role in Treatment Adherence

    Many women discontinue adjuvant endocrine therapy (AET) because of adverse events (AEs), and only half remain adherent at five years. Researchers from the University of Southern California, Los Angeles, found that continued social support for those women may improve AET adherence. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    Cancer treatments

    FDA Modifies Use of Erlotinib in NSCLC, Used Only in Patients With EGFR Tumor Mutations

    On October 18, 2016, the U.S. Food and Drug Administration modified the indication for erlotinib (TARCEVA, Astellas Pharm Global Development Inc.) for treatment of non-small cell lung cancer (NSCLC) to limit use to patients whose tumors have specific epidermal growth factor receptor (EGFR) mutations.
    October 19, 2016
    Patient assistance programs

    Help Your Patients Navigate the Financial Challenges of Cancer

    Every nurse has been in a situation where he or she is staring at a discharge document, thinking, “This patient will need an immense amount of outside support to adhere to this treatment plan.”
    October 04, 2016
    Treatment adherence

    FDA Modifies Nivolumab Dosing for Three Indications

    On September 13, 2016, the U.S. Food and Drug Administration modified the dosage regimen for nivolumab (Opdivo®, Bristol-Myers Squibb Co.) for the currently approved indications for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer. The currently approved recommended dosage regimens were modified to 240 mg intravenously (IV) every two weeks.
    September 15, 2016
    Cancer screening medical device
    Cancer recurrence

    Missing Radiation Therapy Sessions Increases Risk of Recurrence

    Patients who miss two or more regularly scheduled radiation therapy sessions may be at increased risk of recurrence even if they eventually complete their course of treatment, researchers reported after a recent study.
    April 05, 2016
    An oncology nurse promotes oral adherence
    Oral adherence

    Oncology Nurses Can Use Evidence to Promote Oral Adherence

    Administration of chemotherapy drugs has shifted dramatically in the past 15 years from parenteral to oral administration. This change requires patients to self-manage their chemotherapy. Patients need to understand important medication administration tasks: right dose, right time, right route, and right drug.
    January 05, 2016
    Oncology nurses help patients adhere to oral chemotherapy
    Oral adherence

    How Can Nurses Help Patients Adhere to Their Oral Chemotherapy?

    Oral chemotherapy, like IV chemotherapy, effectively helps patients fight cancer and may have similar side effects to its IV counterparts. Self-administration of oral chemotherapy may be convenient, but it is still chemotherapy and requires extra caution.
    January 05, 2016
    Improving ahderence to oral treatment plans
    Oral adherence

    Adherence to Oral Agents for Cancer

    Adherence to oral agents for cancer (OACs) is an important issue in the oncology setting. Unlike IV agents, which are typically administered in a controlled environment by oncology nurses, OACs are self-administered at home with little professional oversight. The potential for medication error or nonadherence cannot be underestimated, but oncology nurses are in a key position to spearhead initiatives aimed at improving patient education and adherence for OACs.
    January 05, 2016
    Cancer treatments

    Understand Medication Adherence to Oral Oncology Agents

    More than half of new cancer treatment regimens involve an oral route of administration because oral drugs are more manageable and convenient for patients. However, oral medications pose challenges with regard to patient adherence.
    April 25, 2015
    Lymphedema as an oncology treatment side effect
    Clinical practice

    The Case of the Severe Sudden-Onset Swelling

    Gina is filling in for the triage nurse at her facility’s outpatient solid tumor department. She receives a call from a patient who reports severe swelling in her left arm after returning from a trip on the opposite side of the United States. She says the skin in her arm and hand is quite tight, and that her hand was throbbing when she woke up this morning. What would you do?
    October 15, 2013
    bowel care regimen
    Clinical practice

    The Case of the Compacted Colon

    Bob, a 61-year-old man with multiple myeloma, calls his hematologist’s office complaining of worsening constipation despite increasing his fiber and liquid intake. Yesterday, he stopped taking his ondansetron because he remembered that it can cause constipation, but now he’s nauseated in addition to being constipated. What would you do?
    May 07, 2013
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲